We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Citing Deaths, Risk Assessment, Roche, Biogen End RA Trial
Citing Deaths, Risk Assessment, Roche, Biogen End RA Trial
May 26, 2010
Roche and Biogen Idec are ending development of ocrelizumab for treatment of rheumatoid arthritis (RA) following deaths in clinical trials and a disappointing risk-benefit assessment that showed the drug was not favorable compared with current treatments.